847553-89-3
847553-89-3
Chemical Structure
SHA 68
- CAS No.: 847553-89-3
- Formula:C26H24FN3O3
- Molecular Weight:445.49
IUPAC Name: N-(4-fluorobenzyl)-3-oxo-1,1-diphenyltetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxamide
InChIKey: SFRQIPRTNYHJHP-UHFFFAOYSA-N
SMILES: O=C(N1CC2N(C(OC2(C3=CC=CC=C3)C4=CC=CC=C4)=O)CC1)NCC5=CC=C(F)C=C5
Biological Activity: SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC50s of 22.0 and 23.8 nM for NPSR Asn107 and NPSR Ile107, respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SHA 68 | 99.84% | SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC50s of 22.0 and 23.8 nM for NPSR Asn107 and NPSR Ile107, respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SHA 68 (Standard) | ≥98% | SHA 68 (Standard) is the analytical standard of SHA 68. This product is intended for research and analytical applications. SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC50s of 22.0 and 23.8 nM for NPSR Asn107 and NPSR Ile107, respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Okamura N, et al. Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.J Pharmacol Exp Ther. 2008 Jun;325(3):893-901. [Content Brief]
- [2]. Ensho T, et al. Neuropeptide S increases motor activity and thermogenesis in the rat through sympathetic activation.Neuropeptides. 2017 Oct;65:21-27. [Content Brief]
Keywords
